Loading
companiesCompany
ONK Therapeutics
ONK Therapeutics, based in Galway, Ireland, is developing off-the-shelf natural killer cell therapies that are gene-edited and given two ways to kill cancer cells at once. It is a private, preclinical-stage company spun out of University of Galway research.
Overview
ONK Therapeutics is a privately held Irish company founded in 2015 on the NK cell and apoptosis research of Prof Michael O'Dwyer and collaborators at the University of Galway. It is developing next-generation off-the-shelf, optimally engineered natural killer (NK) cell therapies for haematological malignancies and solid tumours. Its platform combines a chimeric antigen receptor against a tumour antigen with a TRAIL variant that engages the death receptor pathway (DR4 or DR5), a dual-targeted design intended to improve efficacy and reduce antigen escape; the company also holds a European patent on CISH knockout in NK cells. In December 2023 ONK announced a research partnership with NAYA Biosciences to combine its NK cells with FLEX-NK bispecific antibodies. No clinical trial or financing round was described on the fetched pages.
Notes
top- No funding round sourced (company is private and Irish, no SEC filings). Most recent news item on the site is dated December 2023, so current activity level is uncertain.
Similar pages
- CompanyIndapta Therapeutics
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- PersonKatayoun Rezvani
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- TechnologyNK cell therapy and CAR-NK
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- TechnologyAllogeneic donor and iPSC master cell banks
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- IdeaQualify one iPSC master cell bank once for many off-the-shelf cell products
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- InstitutionMasonic Cancer Center, University of Minnesota
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- CompanyFate Therapeutics
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- TermNK cell
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.